comparemela.com

Astellas Company News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

- Leverages Poseida s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ Astellas.

Xyphos biosciencesAstellas pharmaKristin yaremaNaoki okamuraAdam pearsonAstellas companyPoseida therapeutics incExchange commissionXyphos biosciences incAreas of interest astellas pharma incAstellas pharma incPoseida therapeuticsChimeric antigen receptorChief strategy officerPrimary focusFocus area approach

Opthea : Quarterly Activity Report - Form 6-K

Quarterly Activity Report Q3 FY24 Highlights • Completion of enrolment in first trial of sozinibercept s Phase 3 pivotal program.

United statesJulie clarkXand linkedinArshad khananiSilvana guerci lenaArshadm khananiFred guerardAstellas companyGenentech united states incFellowship at sierra eye associatesExchange commissionLeadership teamUniversity of nevadaClinical developmentDrug administrationLomb corporation

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ Iveric Bio, An Astellas Company , today announced the U.S. Centers for Medicare and Medicaid Services.

Naoki okamuraMichael petroutsasIveric bioMedicaid servicesAstellas pharma incAstellas companyAstellas pharma us incUs centers for medicareHealthcare common procedure coding systemFocus area approach

Opthea Appoints Arshad M Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

University of nevadaUnited statesFrederic guerardArshadm khananiRudi michelsonMacula societyOpthea limitedReno school of medicineMonsoon communicationsAmerican society of retina specialistsFellowship at sierra eye associatesExchange commissionWilmer eye institute at johns hopkins universityClinical researchAstellas companySierra eye associates

Opthea Appoints Arshad M Khanani, MD, MA, FASRS, as Chief Medical Advisor - Opthea (NASDAQ:OPT)

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive

United statesUniversity of nevadaArshadm khananiFrederic guerardRudi michelsonClinical researchOpthea limitedRetina societyExchange commissionMonsoon communicationsMacula societyAstellas companyReno school of medicineSierra eye associatesWilmer eye institute at johns hopkins universityAmerican society of retina specialists

vimarsana © 2020. All Rights Reserved.